News

Dan Ignaszewski explains how the national advocacy campaign aims to unite patients, researchers, and clinicians to protect NEI’s independence and ensure vision research funding.

Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy to explore new treatment options and improve patient outcomes.

The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company after the COAST trial failed to meet its primary end point.

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some cases, blindness.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next steps in ongoing research.

jCyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida.

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

Eyestem Research secures $10 million funding to advance innovative retinal therapies, aiming for global expansion and promising trial results.

4D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for potential market approval.

A complex case of uveitis linked to syphilis highlights the need for thorough history-taking and multidisciplinary management in diagnosis and treatment.

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

The acquisition focuses on LayerBio's OcuRing-K technology, with plans to initiate the next clinical trial.

Steel and the Glaucoma Research Foundation have a relationship spanning over a decade.

Advanced imaging and awareness of systemic risk factors are essential.

The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated in subjects with non-proliferative diabetic retinopathy

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

Hidden signs of systemic disease, including heart attacks, may first reveal themselves through visual symptoms or subtle patient cues in the exam chair.

Current applications and future outlook on integrating robotic technology in the operating room.

Real-time data analysis and intelligent automation help streamline key steps.